Miguel Angel Tejada Neyra1, Ulf Neuberger1, Annekathrin Reinhardt2, Gianluca Brugnara1, David Bonekamp3, Martin Sill4,5,6, Antje Wick7, David T W Jones4,5,6, Alexander Radbruch3, Andreas Unterberg8, Jürgen Debus9,10, Sabine Heiland1, Heinz-Peter Schlemmer3, Christel Herold-Mende8, Stefan Pfister4,5,6,11, Andreas von Deimling2,12, Wolfgang Wick7,13, David Capper2,14,15, Martin Bendszus1, Philipp Kickingereder1. 1. Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany. 2. Department of Neuropathology, University of Heidelberg Medical Center, Heidelberg, Germany. 3. Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany. 5. Division of Pediatric Neurooncology, DKFZ, Heidelberg, Germany. 6. German Cancer Consortium (DKTK) Core Center Heidelberg, Heidelberg, Germany. 7. Neurology Clinic, University of Heidelberg Medical Center, Heidelberg, Germany. 8. Department of Neurosurgery, University of Heidelberg Medical Center, Heidelberg, Germany. 9. Department of Radiation Oncology, University of Heidelberg Medical Center, Heidelberg Institute of Radiation Oncology (HIRO) and National Center for Radiation Research in Oncology (NCOR), Heidelberg, Germany. 10. Molecular and Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and DKFZ, Heidelberg, Germany. 11. Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany. 12. DKTK, Clinical Cooperation Unit Neuropathology, DKFZ, Heidelberg, Germany. 13. Clinical Cooperation Unit Neurooncology, DKTK, DKFZ, Heidelberg, Germany. 14. Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute for Neuropathology, Berlin, Germany. 15. DKTK, Partner Site Berlin, DKFZ, Heidelberg, Germany.
Abstract
Background: This study aims to evaluate the impact of tumor location on key molecular alterations on a single voxel level in patients with newly diagnosed glioma. Methods: A consecutive series of n = 237 patients with newly diagnosed glioblastoma and n = 131 patients with lower-grade glioma was analyzed. Volumetric tumor segmentation was performed on preoperative MRI with a semi-automated approach and images were registered to the standard Montreal Neurological Institute 152 space. Using a voxel-based lesion symptom mapping (VLSM) analysis, we identified specific brain regions that were associated with tumor-specific molecular alterations. We assessed a predefined set of n = 17 molecular characteristics in the glioblastoma cohort and n = 2 molecular characteristics in the lower-grade glioma cohort. Permutation adjustment (n = 1000 iterations) was used to correct for multiple testing, and voxel t-values that were greater than the t-value in >95% of the permutations were retained in the VLSM results (α = 0.05, power > 0.8). Results: Tumor location predilection for isocitrate dehydrogenase (IDH) mutant tumors was found in both glioblastoma and lower-grade glioma cohorts, each showing a concordant predominance in the frontal lobe adjacent to the rostral extension of the lateral ventricles (permutation-adjusted P = 0.021 for the glioblastoma and 0.013 for the lower-grade glioma cohort). Apart from that, the VLSM analysis did not reveal a significant association of the tumor location with any other key molecular alteration in both cohorts (permutation-adjusted P > 0.05 each). Conclusion: Our study highlights the unique properties of IDH mutations and underpins the hypothesis that the rostral extension of the lateral ventricles is a potential location for the cell of origin in IDH-mutant gliomas.
Background: This study aims to evaluate the impact of tumor location on key molecular alterations on a single voxel level in patients with newly diagnosed glioma. Methods: A consecutive series of n = 237 patients with newly diagnosed glioblastoma and n = 131 patients with lower-grade glioma was analyzed. Volumetric tumor segmentation was performed on preoperative MRI with a semi-automated approach and images were registered to the standard Montreal Neurological Institute 152 space. Using a voxel-based lesion symptom mapping (VLSM) analysis, we identified specific brain regions that were associated with tumor-specific molecular alterations. We assessed a predefined set of n = 17 molecular characteristics in the glioblastoma cohort and n = 2 molecular characteristics in the lower-grade glioma cohort. Permutation adjustment (n = 1000 iterations) was used to correct for multiple testing, and voxel t-values that were greater than the t-value in >95% of the permutations were retained in the VLSM results (α = 0.05, power > 0.8). Results:Tumor location predilection for isocitrate dehydrogenase (IDH) mutant tumors was found in both glioblastoma and lower-grade glioma cohorts, each showing a concordant predominance in the frontal lobe adjacent to the rostral extension of the lateral ventricles (permutation-adjusted P = 0.021 for the glioblastoma and 0.013 for the lower-grade glioma cohort). Apart from that, the VLSM analysis did not reveal a significant association of the tumor location with any other key molecular alteration in both cohorts (permutation-adjusted P > 0.05 each). Conclusion: Our study highlights the unique properties of IDH mutations and underpins the hypothesis that the rostral extension of the lateral ventricles is a potential location for the cell of origin in IDH-mutant gliomas.
Authors: Elizabeth Bates; Stephen M Wilson; Ayse Pinar Saygin; Frederic Dick; Martin I Sereno; Robert T Knight; Nina F Dronkers Journal: Nat Neurosci Date: 2003-05 Impact factor: 24.884
Authors: Hinke F van Thuijl; Tali Mazor; Brett E Johnson; Shaun D Fouse; Koki Aihara; Chibo Hong; Annika Malmström; Martin Hallbeck; Jan J Heimans; Jenneke J Kloezeman; Marie Stenmark-Askmalm; Martine L M Lamfers; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchell S Berger; Peter Söderkvist; Barry S Taylor; Annette M Molinaro; Pieter Wesseling; Jaap C Reijneveld; Susan M Chang; Bauke Ylstra; Joseph F Costello Journal: Acta Neuropathol Date: 2015-02-28 Impact factor: 17.088
Authors: Pierre Bady; Davide Sciuscio; Annie-Claire Diserens; Jocelyne Bloch; Martin J van den Bent; Christine Marosi; Pierre-Yves Dietrich; Michael Weller; Luigi Mariani; Frank L Heppner; David R Mcdonald; Denis Lacombe; Roger Stupp; Mauro Delorenzi; Monika E Hegi Journal: Acta Neuropathol Date: 2012-07-19 Impact factor: 17.088
Authors: B M Ellingson; A Lai; R J Harris; J M Selfridge; W H Yong; K Das; W B Pope; P L Nghiemphu; H V Vinters; L M Liau; P S Mischel; T F Cloughesy Journal: AJNR Am J Neuroradiol Date: 2012-09-20 Impact factor: 3.825
Authors: David Bonekamp; Kim Mouridsen; Alexander Radbruch; Felix T Kurz; Oliver Eidel; Antje Wick; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Leif Østergaard; Philipp Kickingereder Journal: J Cereb Blood Flow Metab Date: 2016-07-21 Impact factor: 6.200
Authors: Benedikt Wiestler; David Capper; Tim Holland-Letz; Andrey Korshunov; Andreas von Deimling; Stefan Michael Pfister; Michael Platten; Michael Weller; Wolfgang Wick Journal: Acta Neuropathol Date: 2013-08-01 Impact factor: 17.088
Authors: Thomas S Jacques; Alexander Swales; Monika J Brzozowski; Nico V Henriquez; Jacqueline M Linehan; Zaman Mirzadeh; Catherine O' Malley; Heike Naumann; Arturo Alvarez-Buylla; Sebastian Brandner Journal: EMBO J Date: 2009-11-19 Impact factor: 11.598
Authors: James M Snyder; Raymond Y Huang; Harrison Bai; Vikram R Rao; Susannah Cornes; Jill S Barnholtz-Sloan; David Gutman; Rebecca Fasano; Erwin G Van Meir; Daniel Brat; Jennifer Eschbacher; John Quackenbush; Patrick Y Wen; Jong Woo Lee Journal: Neurooncol Adv Date: 2021-06-24
Authors: Even Hovig Fyllingen; Lars Eirik Bø; Ingerid Reinertsen; Asgeir Store Jakola; Lisa Millgård Sagberg; Erik Magnus Berntsen; Øyvind Salvesen; Ole Solheim Journal: Acta Neurochir (Wien) Date: 2021-03-20 Impact factor: 2.216
Authors: Maarten M J Wijnenga; Sebastian R van der Voort; Pim J French; Stefan Klein; Hendrikus J Dubbink; Winand N M Dinjens; Peggy N Atmodimedjo; Marius de Groot; Johan M Kros; Joost W Schouten; Clemens M F Dirven; Arnaud J P E Vincent; Marion Smits; Martin J van den Bent Journal: Neurooncol Adv Date: 2019-05-31